Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema

Benjamin J Thomas, Yoshihiro Yonekawa, Jeremy D Wolfe, Tarek S Hassan Department of Vitreoretinal Surgery, William Beaumont Hospital, Royal Oak, MI, USA Objective: To compare the effects of intravitreal ranibizumab (RZB) or dexamethasone (DEX) intravitreal implant in cases of recalcitrant diabetic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas BJ, Yonekawa Y, Wolfe JD, Hassan TS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Aflibercept bevacizumab central macular thickness macular edema dexamethasone implant diabetic macular edema diabetic retinopathy ranibizumab Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/07ff5ee889c64ddbbcda32c77b5939e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:07ff5ee889c64ddbbcda32c77b5939e7
record_format	dspace
spelling	oai:doaj.org-article:07ff5ee889c64ddbbcda32c77b5939e72021-12-02T04:22:33ZContralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema1177-5483https://doaj.org/article/07ff5ee889c64ddbbcda32c77b5939e72016-08-01T00:00:00Zhttps://www.dovepress.com/contralateral-eye-to-eye-comparison-of-intravitreal-ranibizumab-and-a--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Benjamin J Thomas, Yoshihiro Yonekawa, Jeremy D Wolfe, Tarek S Hassan Department of Vitreoretinal Surgery, William Beaumont Hospital, Royal Oak, MI, USA Objective: To compare the effects of intravitreal ranibizumab (RZB) or dexamethasone (DEX) intravitreal implant in cases of recalcitrant diabetic macular edema (DME).Methods: Retrospective, interventional study examining patients with symmetric bilateral, center-involved DME recalcitrant to treatment with RZB, who received DEX in one eye while the contralateral eye continued to receive RZB every 4–5 weeks for a study period of 3 months.Results: Eleven patients (22 eyes) were included: mean logarithm of the minimal angle of resolution (logMAR) visual acuity (VA) for the DEX arm improved from 0.415 (standard deviation [SD] ±0.16) to 0.261 (SD ±0.18) at final evaluation, and mean central macular thickness (CMT) improved from 461 µm (SD ±156) to 356 µm (SD ±110; net decrease: 105 µm, P=0.01). Mean logMAR VA for the RZB arm improved from 0.394 (SD ±0.31) to 0.269 (SD ±0.19) at final evaluation. Mean CMT improved from 421 µm (SD ±147) to 373 µm (SD ±129; net decrease: 48 µm, P=0.26).Conclusion: A subset of recalcitrant DME patients demonstrated significant CMT reduction and VA improvement after a single DEX injection. Keywords: aflibercept, bevacizumab, central macular thickness, macular edema, dexamethasone implant, diabetic macular edema, diabetic retinopathy, ranibizumabThomas BJYonekawa YWolfe JDHassan TSDove Medical PressarticleAfliberceptbevacizumabcentral macular thicknessmacular edemadexamethasone implantdiabetic macular edemadiabetic retinopathyranibizumabOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 1679-1684 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aflibercept bevacizumab central macular thickness macular edema dexamethasone implant diabetic macular edema diabetic retinopathy ranibizumab Ophthalmology RE1-994
spellingShingle	Aflibercept bevacizumab central macular thickness macular edema dexamethasone implant diabetic macular edema diabetic retinopathy ranibizumab Ophthalmology RE1-994 Thomas BJ Yonekawa Y Wolfe JD Hassan TS Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
description	Benjamin J Thomas, Yoshihiro Yonekawa, Jeremy D Wolfe, Tarek S Hassan Department of Vitreoretinal Surgery, William Beaumont Hospital, Royal Oak, MI, USA Objective: To compare the effects of intravitreal ranibizumab (RZB) or dexamethasone (DEX) intravitreal implant in cases of recalcitrant diabetic macular edema (DME).Methods: Retrospective, interventional study examining patients with symmetric bilateral, center-involved DME recalcitrant to treatment with RZB, who received DEX in one eye while the contralateral eye continued to receive RZB every 4–5 weeks for a study period of 3 months.Results: Eleven patients (22 eyes) were included: mean logarithm of the minimal angle of resolution (logMAR) visual acuity (VA) for the DEX arm improved from 0.415 (standard deviation [SD] ±0.16) to 0.261 (SD ±0.18) at final evaluation, and mean central macular thickness (CMT) improved from 461 µm (SD ±156) to 356 µm (SD ±110; net decrease: 105 µm, P=0.01). Mean logMAR VA for the RZB arm improved from 0.394 (SD ±0.31) to 0.269 (SD ±0.19) at final evaluation. Mean CMT improved from 421 µm (SD ±147) to 373 µm (SD ±129; net decrease: 48 µm, P=0.26).Conclusion: A subset of recalcitrant DME patients demonstrated significant CMT reduction and VA improvement after a single DEX injection. Keywords: aflibercept, bevacizumab, central macular thickness, macular edema, dexamethasone implant, diabetic macular edema, diabetic retinopathy, ranibizumab
format	article
author	Thomas BJ Yonekawa Y Wolfe JD Hassan TS
author_facet	Thomas BJ Yonekawa Y Wolfe JD Hassan TS
author_sort	Thomas BJ
title	Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
title_short	Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
title_full	Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
title_fullStr	Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
title_full_unstemmed	Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
title_sort	contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/07ff5ee889c64ddbbcda32c77b5939e7
work_keys_str_mv	AT thomasbj contralateraleyetoeyecomparisonofintravitrealranibizumabandasustainedreleasedexamethasoneintravitrealimplantinrecalcitrantdiabeticmacularedema AT yonekaway contralateraleyetoeyecomparisonofintravitrealranibizumabandasustainedreleasedexamethasoneintravitrealimplantinrecalcitrantdiabeticmacularedema AT wolfejd contralateraleyetoeyecomparisonofintravitrealranibizumabandasustainedreleasedexamethasoneintravitrealimplantinrecalcitrantdiabeticmacularedema AT hassants contralateraleyetoeyecomparisonofintravitrealranibizumabandasustainedreleasedexamethasoneintravitrealimplantinrecalcitrantdiabeticmacularedema
_version_	1718401229405552640

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema

Ejemplares similares